BioVie Inc.'s Decentralized Parkinson's Trial: Sunrise PD and Bezistarum

Sunrise PD: A Decentralized Approach to Parkinson's

• 💡 The Sunrise PD trial by BioVie Inc. is a hybrid, decentralized Phase 2 study for early-stage Parkinson's disease.
• 🎯 This innovative trial design incorporates in-home visits, telehealth, and digital assessments to reduce participation barriers, especially for individuals with mobility challenges.

Bezistarum: Novel Oral Therapy

• 🔬 Bezistarum is an oral therapy being evaluated in the trial, designed to target key drivers of Parkinson's: inflammation and insulin resistance.
• 📈 Early results suggest Bezistarum may offer significant improvements in both motor and non-motor symptoms of Parkinson's.

Trial Milestones and Partnerships

• 🗓️ Top-line data from the pivotal Sunrise PD trial is anticipated by late 2025.
• 🤝 BioVie Inc. is collaborating with organizations like the Michael J. Fox Foundation to enhance awareness and patient recruitment for the study.